Effect of recombinant human erythropoietin on vascular access.
The use of recombinant human erythropoietin (r-HuEPO) corrects the anemia of chronic hemodialysis (HD) patients and improves their quality of life. The role of r-HuEPO in the genesis of graft thrombosis is controversial. A retrospective study was conducted of 46 stable chronic HD patients receiving r-HuEPO. It showed an increase in graft thrombosis in those who received the drug.
Dy
G R
GR
Kraftsow Division of Nephrology, Albert Einstein Medical Center, Philadelphia 19141.
Bloom
E J
EJ
Ijelu
G K
GK
Merritts
G W
GW
Kramer
M S
MS
Raja
R M
RM
D000368:Aged; D001166:Arteriovenous Shunt, Surgical; D001807:Blood Vessel Prosthesis; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D006083:Graft Occlusion, Vascular / Q000097:blood / Q000139:chemically induced; D006400:Hematocrit; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011138:Polytetrafluoroethylene; D011994:Recombinant Proteins / Q000008:administration & dosage; D006435:Renal Dialysis; D012189:Retrospective Studies; D012307:Risk Factors
D011994:Recombinant Proteins; D004921:Erythropoietin; D011138:Polytetrafluoroethylene